Boston Scientific Corp (BSX) Fair Value & Analysis
Healthcare · US · Market cap $63.4B · ISIN US1011371077
What is Boston Scientific Corp really worth?
Boston Scientific Corp
BSX · US
A solid business, but trading 53% above our fair value of $30.73.
Strengths
Risks
Fair value as of: Aug 31, 2026
From 24 valuation models · updated 5 days ago
Share price −4.4% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($42.64). The favourable scenario is already priced in.
- Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range ($21.30 to $42.64) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 31, 2026.
How to read this chart
60‑month range $35.24 – $108.14 · fair‑value band $21.30 – $42.64 · the $46.95 price screens above the $30.73 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Aug 31, 2026.
Analysis
Boston Scientific Corp (BSX) currently trades at $46.95, while our model-based Fair Value estimate is $30.73, implying the stock looks roughly 52.8% overvalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of $39.15 per share, and 1 of the 24 models we run sit above the $46.95 price. Bear case: the Economic Profit group reads lowest at $9.90, and 23 of the 24 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Boston Scientific Corp generated revenue of $20.6B at a net margin of 17.3%. Revenue grew 11.6% year over year. It earns a return on equity of 14.7%. Net debt stands at $10.4B. Fundamentals as of Aug 31, 2026
Our scenario range runs from $21.30 (bear case) to $42.64 (bull case); at $46.95, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 57% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −35%, BSX screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly $1.62 per share, which is 5.3 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: DCF Models ($39.15) versus Economic Profit ($9.90). Highest evidence: FCF DCF (77).
Notify me when BSX reaches fair value
Put BSX on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 31, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 65 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.
Full company description
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Boston Scientific Corp reported revenue of $20.1B in FY2025 versus $11.9B in FY2021, a compound +14.0%/yr. Reported net income was $2.9B in FY2025, compounding +29.1%/yr from FY2021.
BSX screens 53% overvalued. Compare with Abbott Laboratories, →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Did Recalls And Cyberattack Disruptions Just Shift Boston Scientific's (BSX) Investment Narrative?
- Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
- Boston Scientific (BSX) Could Be 23% Undervalued After Recalls And Cyber Incident
- Boston Scientific (BSX) Issues Multiple Worldwide Product Recalls
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 35/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $112.47 | $74.79 | −34% |
| Stryker Corporation SYK | $322.12 | $186.28 | −42% |
| Medtronic plc MDT | $89.97 | $65.57 | −27% |
| Edwards Lifesciences Corporation EW | $89.78 | $41.02 | −54% |
| Siemens Healthineers AG SHL | €39.52 | €33.87 | −14% |
| DexCom, Inc DXCM | $90.82 | $38.95 | −57% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | −14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | −39% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | −2% |
| STERIS plc STE | $232.39 | $175.29 | −25% |
Compare Boston Scientific Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Boston Scientific Corp (BSX) overvalued or undervalued?
What is the fair value of BSX?
What is the quality score of BSX?
What is the revenue of Boston Scientific Corp (BSX)?
What is the net profit margin of BSX?
Watch Boston Scientific Corp in the live analysis
One click puts Boston Scientific Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.